Showing 4601-4610 of 5957 results for "".
- Euclid Systems Launches MyEuclid Customer Portalhttps://modernod.com/news/euclid-systems-launches-myeuclid-customer-portal/2480579/Euclid Systems announced an initial launch of MyEuclid, a new interactive, web-based customer portal designed to help drive practice efficiency and optimize Euclid Ortho-K fits. Used on millions of eyes a
- Avellino Enters Into Distribution Agreement With Keeler to Sell Genetic Eye Test AvaGenhttps://modernod.com/news/avellino-enters-into-distribution-agreement-with-keeler-to-sell-genetic-eye-test-avagen/2480576/Avellino Lab USA and Keeler have entered into an agreement where Keeler will distribute AvaGen on its US website. Terms of the deal were not disclosed. AvaGen is the first genetic test that helps determine a patient’s risk of keratoconus and the presence
- Seoul Semiconductor Proves the Effect of SunLike Lighting on Myopia Improvementhttps://modernod.com/news/seoul-semiconductor-proves-the-effect-of-sunlike-lighting-on-myopia-improvement/2480573/Seoul Semiconductor announced that it has confirmed SunLike lighting’s effect on improving myopia, along with SERI_Singapore Eye Research Institute. In order to prove the correlation between health and SunLike, a natural lighting technology developed through years of R&D,
- Market Scope: Global Refractive Market Rebounds Strongly After COVID-19https://modernod.com/news/market-scope-global-refractive-market-rebounds-strongly-after-covid-19/2480568/The impact of COVID-19 shutdowns initially sharply reduced the number of refractive surgical procedures, but demand has bounced back strongly, with the use of protec
- Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trials for Presbyopia and Dry Eye Diseasehttps://modernod.com/news/glaukos-announces-first-patient-enrolled-in-phase-2-clinical-trial-for-presbyopia/2480564/Glaukos announced that it has enrolled the first patient into a phase 2 clinical trial of GLK-302 for the treatment of presbyopia and GLK-301 for the treatment of signs and symptoms of dry eye disease (DED). GLK-302 is the second investigational drug candidate utilizing Glaukos&rsq
- Alcon Completes Acquisition of Ivantis, Bringing Hydrus Microstent into Its Global Surgical Portfoliohttps://modernod.com/news/alcon-completes-acquisition-of-ivantis-bringing-hydrus-microstent-into-its-global-surgical-portfolio/2480555/Alcon announced the closing of its previously announced acquisition of Ivantis, developer of the Hydrus Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients in connection with cataract surge
- Glaukos Announces FDA 510(k) Clearance of iPRIME Viscodelivery Systemhttps://modernod.com/news/glaukos-announces-fda-510k-clearance-of-iprime-viscodelivery-system/2480553/Glaukos announced that it has received 510(k) clearance from the FDA for the iPRIME Viscodelivery System, a sterile, single-use, minimally-invasive device for the delivery of viscoelastic fluid during ophthalmic surgery. “Since the introduction of our first&nb
- Kriya Expands Gene Therapy Pipeline and Establishes Its Rare Disease Therapeutic Area Division with Acquisition of Warden Biohttps://modernod.com/news/kriya-expands-gene-therapy-pipeline-and-establishes-its-rare-disease-therapeutic-area-division-with-the-acquisition-of-warden-bio/2480550/Gene therapy company Kriya Therapeutics announced that it has acquired Warden Bio, a company developing novel AAV-mediated gene therapies for glycogen storage disorders (GSDs). Under the agreement, Kriya has obtained exclusive rights to Warden Bio’s five preclinical gene therapy programs.</
- EyeQue Launches MyReaderNumber App: Personalized Results for Reading and Computer Glasseshttps://modernod.com/news/eyeque-launches-myreadernumber-app-personalized-results-for-reading-and-computer-glasses/2480543/EyeQue introduced a first-of-its-kind smartphone app called MyReaderNumber that offers AR technology vision testing for presbyopia. EyeQue’s new AR-powered MyReaderNumber app delivers personalized measurements for both near reading distance and mid-distance (computer us
- New Survey From Bausch + Lomb and Glaucoma Research Foundation Reveals Emotional and Social Impact of Hyperemia on Glaucoma Patientshttps://modernod.com/news/new-survey-from-bausch-lomb-and-glaucoma-research-foundation-reveals-emotional-and-social-impact-of-hyperemia-on-glaucoma-patients/2480542/Bausch + Lomb and Glaucoma Research Foundation (GRF) released new key findings from a survey of glaucoma patients that was designed to gain a greater understanding of the impact that hyperemia can have in the treatment and lives of people living with glaucoma. In the Unit